inclusion criteria: 1. ≥ 18 years of age at the time of signing the informed consent 2. adults with potential exposure, within 8 days, to a specific identified individual with laboratory-confirmed sars-cov-2 infection, symptomatic or asymptomatic 3. participants must not have had covid-19 symptoms within 10 days of dosing 4. negative result from point of care sars-cov-2 serology test at screening 5. contraception used by women of childbearing potential, condom by men 6. able to understand and comply with study requirements/procedures based on the assessment of the investigator

inclusion criteria: 1. ≥ 18 years of age at the time of signing the informed consent 2. adults with potential exposure, within 8 days, to a specific identified individual with laboratory-confirmed sars-cov-2 infection, symptomatic or asymptomatic 3. participants must not have had covid-19 symptoms within 10 days of dosing 4. negative result from point of care sars-cov-2 serology test at screening 5. contraception used by women of childbearing potential, condom by men 6. able to understand and comply with study requirements/procedures based on the assessment of the investigator

inclusion criteria: ≥ 18 years of age at the time of signing the informed consent adults with potential exposure, within 8 days, to a specific identified individual with laboratory-confirmed sars-cov-2 infection, symptomatic or asymptomatic participants must not have had covid-19 symptoms within 10 days of dosing negative result from point of care sars-cov-2 serology test at screening contraception used by women of childbearing potential, condom by men able to understand and comply with study requirements/procedures based on the assessment of the investigator

inclusion criteria: ≥ 18 years of age at the time of signing the informed consent adults with potential exposure, within 8 days, to a specific identified individual with laboratory-confirmed sars-cov-2 infection, symptomatic or asymptomatic participants must not have had covid-19 symptoms within 10 days of dosing negative result from point of care sars-cov-2 serology test at screening contraception used by women of childbearing potential, condom by men able to understand and comply with study requirements/procedures based on the assessment of the investigator

inclusion criteria: 1. ≥ 18 years of age at the time of signing the informed consent 2. adults with potential exposure, within 8 days, to a specific identified individual with laboratory-confirmed sars-cov-2 infection, symptomatic or asymptomatic 3. participants must not have had covid-19 symptoms within 10 days of dosing 4. negative result from point of care sars-cov-2 serology test at screening 5. contraception used by women of childbearing potential, condom by men 6. able to understand and comply with study requirements/procedures based on the assessment of the investigator

inclusion criteria: 1. ≥ 18 years of age at the time of signing the informed consent 2. adults with potential exposure, within 8 days, to a specific identified individual with laboratory-confirmed sars-cov-2 infection, symptomatic or asymptomatic 3. participants must not have had covid-19 symptoms within 10 days of dosing 4. negative result from point of care sars-cov-2 serology test at screening 5. contraception used by women of childbearing potential, condom by men 6. able to understand and comply with study requirements/procedures based on the assessment of the investigator

inclusion criteria: 1. ≥ 18 years of age at the time of signing the informed consent 2. adults with potential exposure, within 8 days, to a specific identified individual with laboratory-confirmed sars-cov-2 infection, symptomatic or asymptomatic 3. participants must not have had covid-19 symptoms within 10 days of dosing 4. contraception used by women of childbearing potential, condom by men

inclusion criteria: 1. ≥ 18 years of age at the time of signing the informed consent 2. adults with potential exposure, within 8 days, to a specific identified individual with laboratory-confirmed sars-cov-2 infection, symptomatic or asymptomatic 3. participants must not have had covid-19 symptoms within 10 days of dosing 4. contraception used by women of childbearing potential, condom by men